Zheng Cui, Ph.D., business lead researcher and associate professor of pathology, announced the study at the Understanding Aging conference in Los Angeles. The scholarly study, given the go-forward by the U.S. Food and Drug Administration, will involve treating human cancer patients with white bloodstream cells from healthy teenagers whose immune systems create cells with high degrees of cancer-fighting activity. The foundation of the study is the scientists’ discovery, released five years back, of a cancer-resistant mouse and their subsequent discovering that white bloodstream cells from that mouse and its offspring healed advanced cancers in common laboratory mice.The randomized trial included 642 sufferers who were receiving chemotherapy for a variety of cancers. Investigators asked them to complete a survey assessing their level of fatigue twice, sleepiness and depression. The initial study was conducted at the second routine of chemotherapy and a follow-up survey was taken through the fourth cycle of chemotherapy. A standard scale, similar to the one used to measure discomfort, asked patients to rate their level of exhaustion from zero to 10 . Anyone who reported a exhaustion value greater than two was randomly assigned to get either 200 mg daily of modafinil or an identical looking placebo pill.